← All organizations

Smith & Nephew

For profitContributed to NME

Also known as: SMITH AND NEPHEW | Smith and Nephew Biotherapeutics | Smith & Nephew Biotherapeutics; Chief Medical Officer | Smith & Nephew, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Aug 1, 2016

Timeline

1850s

Jan 1, 1856
Smith & Nephew— Founded

1960s

Jun 4, 1965
collagenase clostridium histolyticum— Marketing Organization
Jun 4, 1965
collagenase clostridium histolyticum— NDA Secondary Org

1990s

Dec 16, 1997
becaplermin— NDA Organization

2010s

Jan 1, 2012
Healthpoint— Acquired
Mar 12, 2019
Brainlab Orthopaedic— Acquired
Mar 12, 2019
Osiris Therapeutics— Acquired

Drugs by trial phase (18 distinct, 40 trials)

Phase 4 (1 own, 7 via acquisition)

Phase 3 (0 own, 4 via acquisition)

Phase 2 (0 own, 5 via acquisition)

Phase 1 (0 own, 1 via acquisition)

human fibrin

Indications

Studied for

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (13)

NCT02718625Study chairPhase 4Aug 1, 2016
NCT02716519Study chairPhase 4Aug 1, 2016
NCT02718625Study directorPhase 4Aug 1, 2016
NCT02718625Lead sponsorPhase 4Aug 1, 2016
NCT02716519Lead sponsorPhase 4Aug 1, 2016
NCT02581488Lead sponsorPhase 4Oct 1, 2015
NCT02581488Study chairPhase 4Oct 1, 2015
NCT02581488Study directorPhase 4Oct 1, 2015
NCT02154087Study chairPhase 2Jul 1, 2014
NCT02111291Study chairPhase 4Apr 1, 2014
NCT01853384Study directorPhase 3Nov 1, 2013
NCT01853384Study chairPhase 3Nov 1, 2013
NCT01656889CollaboratorPhase 3Aug 1, 2012

Details

Founded: Kingston upon Hull, GB Jan 1, 1856
First NDA: Dec 16, 1997
Last known activity: Aug 1, 2016